Monitoring long-term treatment with pegylated liposomal doxorubicin: How important is intensive cardiac follow-up?

Anti-Cancer Drugs

Volumn 21, Issue 9, 2010, Pages 868-871

  Grenader, Tal ^a   Goldberg, Anthony ^a   Gabizon, Alberto ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

anthracyclines; congestive heart failure; left ventricular ejection fraction; pegylated liposomal doxorubicin

Indexed keywords

DOXORUBICIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CARDIOMYOPATHY; CARDIOTOXICITY; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; DRUG DOSE REDUCTION; DRUG SAFETY; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MALE; MONITORING; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PRIORITY JOURNAL; SARCOMA; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; TONGUE CARCINOMA; TREATMENT DURATION;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG MONITORING; ECHOCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; POLYETHYLENE GLYCOLS; RETROSPECTIVE STUDIES; TIME FACTORS; VENTRICULAR FUNCTION, LEFT;

EID: 77956414363     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32833dc3c4     Document Type: Article

References (16)

1. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998; 339:900-905.
2. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973; 32:302-314.
3. Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91:710-717.
4. Praga C, Beretta G, Vigo PL, Lenaz GR, Pollini C, Bonadonna G, et al. Adriamycin cardiotoxicity: a survey of 1273 patients. Cancer Treat Rep 1979; 63:827-834.
5. Swain SM,Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003; 97:2869-2879.
6. Nousiainen T, Jantunen E, Vanninen E, Hartikainen J. Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients. Br J Cancer 2002; 86:1697-1700.
7. Lewis AB, Crouse VL, Evans W, Takahashi M, Siegel SE. Recovery of left ventricular function following discontinuation of anthracycline chemotherapy in children. Pediatrics 1981; 68:67-72.
8. Safra T. Cardiac safety of liposomal anthracyclines. Oncologist 2003; (Suppl):17-24.
9. Andreopoulou E, Gaiotti D, Kim E, Downey A, Mirchandani D, Hamilton A, et al. Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil): experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer. Ann Oncol 2007; 18:716-721.
10. Safra T, Muggia F, Jeffers S, Tsao-Wei DD, Groshen S, Lyass O, et al. Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500mg/m2. Ann Oncol 2000; 11:1029-1033.
11. Mustafa MH. Decreased risk of cardiotoxicity with long-term use of doxil/ caelyx at high lifetime cumulative doses in patients with AIDS-related Kaposi/Es sarcoma (KS). Proc Am Soc Clin Oncol 2001; 20:(Abstr 2915).
12. O Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, et al. CAELYX Breast Cancer Study Group. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004; 15:440-449.
13. Mason JW, Bristow MR, Billingham ME, Daniels JR. Invasive and noninvasive methods of assessing adriamycin cardiotoxic effects in man: superiority of histopathologic assessment using endomyocardial biopsy. Cancer Treat Rep 1978; 62:857-864.
14. Ewer MS, Martin FJ, Henderson C, Shapiro CL, Benjamin RS, Gabizon AA. Cardiac safety of liposomal anthracyclines. Semin Oncol 2004; 31(Suppl): 161-181.
15. Gabizon AA, Lyass O, Berry GJ, Wildgust M. Cardiac safety of pegylated liposomal doxorubicin (Doxil/Caelyx) demonstrated by endomyocardial biopsy in patients with advanced malignancies. Cancer Invest 2004; 22:663-669.
16. Orlowski RZ, Nagler A, Sonneveld P, Bladé J, Hajek R, Spencer A, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007; 25:3892-3901.